These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 12774797)

  • 1. [Decrease of HIV-1 virus load by nevirapin/efavirenz].
    Dtsch Med Wochenschr; 2003 May; 128(19):1075. PubMed ID: 12774797
    [No Abstract]   [Full Text] [Related]  

  • 2. [Efavirenz--comprehensive status of studies].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():79-81. PubMed ID: 16385886
    [No Abstract]   [Full Text] [Related]  

  • 3. NNRTIs compared in switch group.
    AIDS Patient Care STDS; 2002 Jun; 16(6):302. PubMed ID: 12133265
    [No Abstract]   [Full Text] [Related]  

  • 4. [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].
    van Leth F; Lange JM
    Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1719-22. PubMed ID: 16924943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV/AIDS news: comparable anti-HIV antiviral efficacy of Viramune and Efavirenz--the Lancet publishes first large-scale comparison study.
    Meyer-Kleinmann J
    Infection; 2004 Jun; 32(3):7. PubMed ID: 15230276
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
    Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
    Clin Infect Dis; 2007 Jan; 44(1):120-7. PubMed ID: 17143827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of NNRTIs in antiretroviral-naïve patients.
    Arribas J
    Int J STD AIDS; 2001 Nov; 12 Suppl 4():3-9. PubMed ID: 11589822
    [No Abstract]   [Full Text] [Related]  

  • 8. The tolerability of efavirenz after nevirapine-related adverse events.
    Clarke S; Harrington P; Barry M; Mulcahy F
    Clin Infect Dis; 2000 Sep; 31(3):806-7. PubMed ID: 11017835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of efficacy of efavirenz and nevirapine: lessons learned for cohort analysis in light of the 2NN Study.
    Keiser P; Nassar N; Yazdani B; Armas L; Moreno S
    HIV Clin Trials; 2003; 4(5):358-60. PubMed ID: 14583852
    [No Abstract]   [Full Text] [Related]  

  • 10. [CROI--presentation of new study results. In a comparison of NNRTI nevirapine is equally effective].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():91. PubMed ID: 15373068
    [No Abstract]   [Full Text] [Related]  

  • 11. Can early failure with nevirapine be rescued with efavirenz?
    Briones C; Soriano V; Dona C; Barreiro P; González-Lahoz J
    J Acquir Immune Defic Syndr; 2000 May; 24(1):76-8. PubMed ID: 10877499
    [No Abstract]   [Full Text] [Related]  

  • 12. Safe substitution for efavirenz.
    AIDS Patient Care STDS; 2004 Jan; 18(1):58. PubMed ID: 15080097
    [No Abstract]   [Full Text] [Related]  

  • 13. [Efavirenz and nevirapine plasma levels in HIV-infected patients with hemophilia].
    Martorell M; López RM; Ribera E; Ruiz I; Tural C; Puig L; Monterde J
    Enferm Infecc Microbiol Clin; 2005; 23(6):349-52. PubMed ID: 15970167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efavirenz: resistance and cross-resistance.
    Clotet B
    Int J Clin Pract Suppl; 1999 Jun; 103():21-5. PubMed ID: 10622039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
    Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
    J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nevirapine + efavirenz based salvage therapy in heavily pretreated HIV infected patients.
    Olivieri J
    Sex Transm Infect; 2002 Feb; 78(1):72-3. PubMed ID: 11872871
    [No Abstract]   [Full Text] [Related]  

  • 17. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.
    Veldkamp AI; Harris M; Montaner JS; Moyle G; Gazzard B; Youle M; Johnson M; Kwakkelstein MO; Carlier H; van Leeuwen R; Beijnen JH; Lange JM; Reiss P; Hoetelmans RM
    J Infect Dis; 2001 Jul; 184(1):37-42. PubMed ID: 11398107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Results of the AIDS-In-Europe Study. Non-nucleoside reverse transcriptase inhibitor does not equal non-nucleoside reverse transcriptase inhibitor].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():39. PubMed ID: 11373776
    [No Abstract]   [Full Text] [Related]  

  • 19. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
    Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
    Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy.
    Tashima KT; Caliendo AM; Ahmad M; Gormley JM; Fiske WD; Brennan JM; Flanigan TP
    J Infect Dis; 1999 Sep; 180(3):862-4. PubMed ID: 10438381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.